67Cu-SARTATE

Cu-67 labeled SARTATE · Clarity Pharmaceuticals Ltd

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for 67Cu-SARTATE, covering 2020-04-20 to 2025-09-16. Get the full timeline:

Most recent: Clinical Trial Update: 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma [Phase 1, Phase 2]

See pricing